Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Rheumatology
Volume 2018, Article ID 6150875, 6 pages
https://doi.org/10.1155/2018/6150875
Case Report

Axial Spondyloarthritis and Autosomal Dominant Polycystic Kidney Disease in Two Siblings: A Rare Cooccurrence

1Department of Physical Medicine and Rehabilitation, Bezmialem Foundation University, Istanbul, Turkey
2Department of Nephrology, Gaziosmanpasa Taksim Training and Research Hospital, Istanbul, Turkey

Correspondence should be addressed to Ozan Volkan Yurdakul; moc.oohay@nazo_lukadruy

Received 4 January 2018; Revised 31 January 2018; Accepted 7 February 2018; Published 4 March 2018

Academic Editor: Constantine Saadeh

Copyright © 2018 Ozan Volkan Yurdakul et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. A. Gabow, “Autosomal dominant polycystic kidney disease,” New England Journal of Medicine, vol. 329, no. 5, pp. 332–342, 1993. View at Publisher · View at Google Scholar · View at Scopus
  2. C. J. Willey, J. D. Blais, A. K. Hall, H. B. Krasa, A. J. Makin, and F. S. Czerwiec, “Prevalence of autosomal dominant polycystic kidney disease in the European Union,” Nephrology Dialysis Transplantation, vol. 32, no. 8, pp. 1356–1363, 2017. View at Publisher · View at Google Scholar · View at Scopus
  3. W. E. Sweeney and E. D. Avner, “Molecular and cellular pathophysiology of autosomal recessive polycystic kidney disease (ARPKD),” Cell and Tissue Research, vol. 326, no. 3, pp. 671–685, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. B. Lanktree and A. B. Chapman, “New treatment paradigms for ADPKD: moving towards precision medicine,” Nature Reviews Nephrology, vol. 13, no. 12, pp. 750–768, 2017. View at Publisher · View at Google Scholar · View at Scopus
  5. P. C. Harris and V. E. Torres, “Genetic mechanisms and signaling pathways in autosomal dominant polycystic kidney disease,” Journal of Clinical Investigation, vol. 124, no. 6, pp. 2315–2324, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Rudwaleit, D. van der Heijde, M. A. Khan, J. Braun, and J. Sieper, “How to diagnose axial spondyloarthritis early,” Annals of the Rheumatic Diseases, vol. 63, no. 5, pp. 535–543, 2004. View at Publisher · View at Google Scholar · View at Scopus
  7. E. Dakwar, J. Reddy, F. L. Vale, and J. S. Uribe, “A review of the pathogenesis of ankylosing spondylitis,” Neurosurgical Focus, vol. 24, no. 1, p. E2, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Mercieca, I. E. van der Horst-Bruinsma, and A. A. Borg, “Pulmonary, renal and neurological comorbidities in patients with ankylosing spondylitis; implications for clinical practice,” Current Rheumatology Reports, vol. 16, no. 8, p. 434, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. S. H. Lee, E. J. Lee, S. W. Chung et al., “Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker,” Rheumatology International, vol. 33, no. 7, pp. 1689–1692, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Ben Taarit, H. Ajlani, F. Ben Moussa, T. Ben Abdallah, H. Ben Maiz, and A. Khedher, “Renal involvement in ankylosing spondylitis: concerning 210 cases,” La Revue de Medecine Interne, vol. 26, no. 12, pp. 966–969, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. A. Shukla, M. K. Rai, N. Prasad, and V. Agarwal, “Short-term non-steroid anti-inflammatory drug use in spondyloarthritis patients induces subclinical acute kidney injury: biomarkers study,” Nephron, vol. 135, no. 4, pp. 277–286, 2017. View at Publisher · View at Google Scholar · View at Scopus
  12. E. S. Strobel and E. Fritschka, “Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports,” Clinical Rheumatology, vol. 17, no. 6, pp. 524–530, 1998. View at Publisher · View at Google Scholar
  13. J. Sieper, M. Rudwaleit, X. Baraliakos et al., “The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis,” Annals of the Rheumatic Diseases, vol. 68, no. 2, pp. ii1–i44, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. D. van der Heijde, S. Ramiro, R. Landewe et al., “2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis,” Annals of the Rheumatic Diseases, vol. 76, no. 6, pp. 978–991, 2017. View at Publisher · View at Google Scholar · View at Scopus
  15. A. Whelton, “Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications,” American Journal of Medicine, vol. 106, no. 5, pp. 13s–24s, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. M. D. Murray and D. C. Brater, “Renal toxicity of the nonsteroidal anti-inflammatory drugs,” Annual Review of Pharmacology and Toxicology, vol. 33, pp. 435–465, 1993. View at Publisher · View at Google Scholar
  17. A. El Maghraoui, “Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications,” European Journal of Internal Medicine, vol. 22, no. 6, pp. 554–560, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. E. M. Spithoven, A. Kramer, E. Meijer et al., “Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival–an analysis of data from the ERA-EDTA registry,” Nephrology Dialysis Transplantation, vol. 29, no. 4, pp. iv15–iv25, 2014. View at Google Scholar
  19. E. T. McCarthy, R. Sharma, M. Sharma et al., “TNF-alpha increases albumin permeability of isolated rat glomeruli through the generation of superoxide,” Journal of the American Society of Nephrology, vol. 9, no. 3, pp. 433–438, 1998. View at Google Scholar
  20. A. Jacquet, H. Francois, C. Frangie et al., “IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy,” Nephrology Dialysis Transplantation, vol. 24, no. 11, pp. 3540–3542, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. Y. H. Lee, E. Y. Kim, D. W. Jeong et al., “Complete remission of nephrotic syndrome without resolution of amyloid deposit after anti-tumor necrosis factor alpha therapy in a patient with ankylosing spondylitis,” Journal of Clinical Rheumatology, vol. 22, no. 2, pp. 86–88, 2016. View at Publisher · View at Google Scholar · View at Scopus
  22. G. R. Smith, K. E. Tymms, and M. Falk, “Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis,” Internal Medicine Journal, vol. 34, no. 9-10, pp. 570–572, 2004. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Perl, “Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases,” Nature Reviews Rheumatology, vol. 12, no. 3, pp. 169–182, 2016. View at Publisher · View at Google Scholar · View at Scopus